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ABSTRACT
Chronic alcohol abuse is the third leading cause of preventable death in the United
States. Ethanol metabolism causes liver injury through alterations in hepatic metabolic
state, redox status, and acetaldehyde adduct formations. Increased iron absorption is
associated with chronic ethanol consumption and may play a role in ethanol induced
oxidative stress. We tested the hypothesis that normal labile iron in the liver plays a
role in ethanol related pathological stress, using C57/Bl6 mice pair-fed Lieber-DeCarli
liquid ethanol diets for 11 and 22 weeks. Normal iron group mice received 55mg/kg iron
as ferric citrate, whereas the low iron groups received 5mg/kg. Our findings indicate
that chronic ethanol treatment did not result in discernible differences in oxidant stress
from the controls as measured by 4-HNE residue formation and histological analysis of
liver sections. Additionally, DNA methylation status was unchanged and there were no
differences in glutathione and SAMe indicating no apparent impact on the methionine
cycle. Analysis of hepatic proteins ferritin and transferrin receptor by western blot
confirmed the expected response to the differences in dietary iron. Global protein
acetylation was increased by ethanol treatment and further stimulated in animals fed the
low iron diets. Overall, this study has identified novel interactions between iron
deficiency and ethanol exposure.

xi

CHAPTER 1
LITERATURE REVIEW
1.1 Introduction
Alcohol (ethanol) use is the third leading cause of preventable death in the
United States in addition to being a major economic burden world-wide [1, 2]. It has
been known that long-term ethanol consumption leads to changes in iron homeostasis
that results in iron overload in the liver, leading to the possibility that iron may play a role
in exacerbating the conditions that bring on alcoholic liver disease [3, 4]. However, little,
to no attention has been given to how the interactions of ethanol and iron might change
if dietary iron intake was decreased in chronic ethanol consumption, and more
importantly whether these interactions might result in a pathophysiological change in the
liver. My scientific interests lie in how chronic ethanol exposure and normal to subnormal dietary levels of iron may interact through the generation of oxidant or other
cellular stresses to generate pathological changes in the liver. Oxidative stress is
thought to be a major contributor to many disease processes. Both iron and ethanol
consumption have been independently linked to the generation of free radicals that
cause oxidative stress [5, 6].

Chronic exposure to ethanol alone is known to cause

tissue damage in the liver, impair other important metabolic processes, and increase the
risk of cancer [6]. The purpose of this report is to test the basic hypothesis that dietary
iron enhances ethanol-mediated liver injury. However, before considering their
interactions, it is first necessary to understand the individual processes of iron regulation
and ethanol metabolism in the liver. In this review I will present the most current
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information concerning iron homeostasis and processes in the liver that are affected by
ethanol metabolism including the transmethylation and transsulfuration pathways and
global hepatic lysine acetylation.
1.2 Iron Homeostasis
Iron is an essential element that is important to many cellular processes including
hemoglobin synthesis, enzymes involved in the electron transport chain, and providing
reactive groups such as iron-sulfur clusters, etc. However, iron can be toxic when not
bound to protein due to the ability of free iron to generate free radicals that cause
oxidative stress. Particularly important to this process is the Fenton reaction (Figure 1),
where divalent iron reacts with hydrogen peroxide to form hydroxide and the hydroxyl
radical. When coupled with the ability of the superoxide anion to reduce trivalent iron to
divalent iron, producing oxygen, the net reaction is called the Haber-Weiss reaction
(Figure 1). Both because of the vital roles it fills and its ability to damage cellular
components, the body has developed elaborate mechanisms to regulate iron both
systemically and at the cellular level.

2

Figure 1. Iron generates oxidative stress. Ferrous iron generates free radicals through the Fenton and
Haber-Weiss reactions.
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Systemic Iron Regulation
The daily demand for iron is dominated by the 20-25mg that are required to
maintain hemoglobin synthesis for erythrocyte production, as 65% of the iron found in
the body is bound to hemoglobin [5]. The demand for iron is met primarily through the
recycling of senescent erythrocytes by macrophages, but 1-2mg comes from dietary
intake. Dietary non-heme iron is transported across the apical membrane of the
intestinal duodenum via a specialized transporter protein. Non-heme iron exists mostly
in the ferric form (Fe3+) and must be reduced in order to be transported into the
enterocytes. Duodenal cytochrome b (Dcytb), a ferric reductase reduces ferric iron to
ferrous (Fe2+) iron concurrently with transportation across the apical membrane. The
absorption of heme bound iron is more efficient, and thought to occur through receptor
mediated endocytosis [7-9]. Loss of iron from the body, aside from bleeding, is minimal,
occurring only through the sloughing of intestinal mucosa and skin cells, and accounts
for roughly 1 mg of iron per day. There are no known mechanisms for the excretion of
iron.
When iron is needed, it is released from the basal membranes of intestinal
enterocytes by the only known iron exporter protein ferroportin, through which iron
enters into blood circulation. The iron quickly binds to transferrin (Tf) in the
bloodstream, which can bind 2 molecules of Fe2+. Tf-bound iron is shuttled through the
portal vein and taken up by liver hepatocytes, facilitated by a type II membrane protein,
the transferrin receptor (TfR) [7]. Because the liver is the primary iron storage site, it
makes sense that systemic iron regulation is also controlled in the liver. Iron sensing
proteins activate a hormone in the liver called hepcidin, through mechanisms that are
4

not well known [10]. Hepcidin regulates systemic iron by degrading ferroportin,
effectively blocking iron release from enterocytes as and macrophages. When systemic
iron is low, hepcidin is down-regulated to facilitate iron release from enterocytes, while
the reverse applies in conditions of iron excess (Figure 2).

5
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Figure 2. Systemic iron regulation. Dietary non-heme iron Fe is reduced to Fe by duodenal
cytochrome b (Dcytb) before being taken up by duodenal enterocytes via the divalent metal transporter
(DMT1). The iron is then either captured by ferritin or transported by the iron exporter protein ferritin and
into the capillaries that drain the intestines. Iron is quickly bound to transferrin (Tf) in the blood which can
bind two molecules of iron. Tf-bound iron is transported to the liver via the hepatic vein and taken up into
hepatocytes by transferrin receptor (TfR). Tf-bound iron in circulation is also used for erythrocyte
production in bone marrow. Circulating red blood cells (RBCs) have a lifespan of 100-120 days. The
senescent RBCs are taken up by macrophages in the spleen where the iron is recycled and returned to
circulation. Systemic iron is controlled by the liver produced hormone hepcidin, which is upregulated
under conditions of iron excess. Hepcidin is released into the blood and degrades ferroportin in
enterocytes and macrophages, effectively blocking iron release.
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Intracellular Iron Regulation
Within various cell types there exists a transient pool of redox reactive,
chelatable, free iron that is referred to as the labile iron pool. Labile iron is tightly
regulated through post-transcriptional control of the expression of the transferrin
receptor transport protein, and the ferritin iron storage protein (Figure 4). Ferritin is a 24
subunit oligomeric mixture of ferritin heavy (FerH) and light chains (FerL). The FerH
subunit contains ferroxidase activity to convert cytosolic Fe2+ to Fe3+, facilitating its
storage within ferritin as ferric oxy-hydroxide phosphate [11]. Ferritin can sequester up
to 4500 Fe3+ ions, which can be released from ferritin by proteosomal or lysosomal
degredation [11].
The expression of TfR and ferritin is controlled by intracellular iron principally
through post-transcriptional mechanisms involving iron response element binding
proteins (IRPs) (Figure 3). A number of genes involved in iron metabolism, transport
and storage contain iron response elements (IREs), which form hairpin structures in
their mRNA to which activated IRPs can bind. The presence of iron de-activates IRP
binding by increasing the affinity of the IRE binding site for iron-sulfur clusters; thus,
when iron is high, more IRPs have a decreased binding affinity toward IREs. The
location of the IRE in a gene dictates whether IRP binding inhibits translation (upstream
location) or increases translation (downstream location). The two classic examples are
transferrin receptor and ferritin. IRP binding, which occurs under low iron conditions,
has the effect of increasing TfR translation by preventing the rapid degradation of TfR
mRNA. Conversely, ferritin translation is decreased because the IRPs physically block
the initiation of translation [11].
7

Thus, when iron is low TfR expression increases, allowing for the cellular uptake
of iron to correct the balance, while ferritin expression is decreased, as iron storage is
not needed when iron is low. During iron excess the reverse occurs: TfR expression
decreases, while ferritin increases. These conditions are illustrated in Figure 4.
Through examination of the steady state protein expression profiles of TfR and ferritin,
one can determine the cell’s iron phenotype, which may provide insight into how
treatments impact intracellular and systemic iron.
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Figure 3. Post transcriptional regulation of ferritin and transferrin receptor. Under conditions of iron
excess iron response element binding proteins (IRPs) become inactive due to the presence of iron
increasing affinity of the iron response element (IRE) binding site for 4Fe-4S clusters. In this state ferritin
translation is active and transferrin receptor (TfR) translation is decreased due to the rapid degradation of
TfR mRNA. When iron is depleted, IRP’s actively bind to the IRE’s on mRNA. Ferritin translation is
blocked by the action of IRP binding to upstream IRE’s, while TfR translation is increased due to IRP’s
stabilizing TfR mRNA and preventing its degradation.
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Figure 4. Intracellular iron regulation in liver hepatocytes. Low intracellular iron stimulates transferrin (Tf)
receptor expression and down-regulates ferritin in order to facilitate the uptake of transferrin bound iron
from blood circulation. Tf—2Fe is taken into the cell by receptor mediated endocytosis. The low pH in
the endosome causes the release of iron from Tf, which is thought to be released into the cytosol by
divalent metal transporter (DMT1). The Tf bound to TfR is returned to the cell membrane and Tf is
released back into the blood. The iron storage protein ferritin, a 24mer consisting of subunits of ferritin
light (FerL) and heavy chains (FerH), increases in response to high intracellular iron levels as transferrin
receptor translation is repressed. Ferritin can also be up-regulated in response to oxidative stress which
2+
can arise from non-Tf bound ferrous iron (Fe ) in the cytosol.
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Iron derived oxidative stress
Iron is an essential metal for life but its high reactivity is a double-edged sword
because it can also be toxic, particularly when there is a disruption in iron homeostasis.
Under normal physiological conditions most iron in the body is bound by protein [5]. For
instance, the metal is usually found bound to Tf in blood circulation or captured by being
stored in ferritin in hepatocytes [5]. However, iron overload can result in an increase of
the labile iron pool, which is the primary source of iron derived oxidative stress in
hepatocytes [12].
Free iron in the cytosol can react with hydrogen peroxide to generate hydroxyl
radicals as indicated in figure 1. Fe2+ can react with lipid peroxides to generate lipid
radicals as well. The reactive oxygen species (ROS) generated from these reactions
can oxidize cell membranes, proteins and DNA, ultimately leading to apoptosis and
other cell damage [5].
Iron overload is not typically a concern for most healthy individuals, although iron
derived ROS may have an influence on the normal aging process [13]. It is mostly
associated with genetic factors such as hereditary hemochromatosis. Individuals with
hereditary hemochromatosis have a 200 fold risk of developing hepatocellular
carcinoma due to excess iron deposition in liver hepatocytes [5]. An activity that is
associated with phenotypic changes that correlate with iron overload is heavy alcohol
consumption, which confers an increased risk of alcoholic liver disease [4, 14].
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1.3 Ethanol Metabolism

When ethanol is consumed it diffuses across cell membranes quite readily and is
absorbed directly from the stomach and small intestines. From there ethanol enters the
bloodstream and is carried into the liver by the portal vein. Whereas other tissues in the
body can metabolize ethanol, the primary site of metabolism is in liver hepatocytes [6].
Ethanol by itself is relatively harmless. However, highly reactive and toxic by-products
are produced during the series of enzymatic reactions that occur in the liver to break
down the alcohol [6].
Ethanol is metabolized by the liver in a series of oxidations to ultimately form
acetate (Figure 5). In moderate alcohol consumers, ethanol is oxidized mainly in the
cytosol of hepatocytes by alcohol dehydrogenase (ADH) to form the intermediate
acetaldehyde. In heavy alcohol consumers about 10% of the ethanol is oxidized by
cytochrome p450 2E1 (CYP2E1) in the microsomes and 2% can be utilized by catalase
in the peroxisomes [4, 15]. Both alternate pathways also result in the formation of
acetaldehyde. The acetaldehyde is further oxidized in the mitochondria by
acetaldehyde dehydrogenase (ALDH) to form acetate. Acetate is activated by acetylcoenzyme A synthetase 2 (AceCS2) in the mitochondria to form acetyl-CoA which is
then utilized by the Krebs cycle to form NADH, CO2 and water as end-products [16].
Alternatively, acetate can enter the bloodstream to be oxidized by mitochondria in other
tissues such as the heart, skeletal muscles, and brain cells to also form NADH, CO2 and
water by the same pathways [6]. In each case, the NADH formed can be utilized by the
electron transport chain to generate ATP [15].
12

Figure 5. Ethanol metabolism overview in liver hepatocytes. Ethanol is oxidized primarily by alcohol
dehydrogenase (ADH), or by catalase and cytochrome p450 (CYPE2E1) to form the toxic intermediate
acetaldehyde. Acetaldehyde is further oxidized in the mitochondria by aldehyde dehydrogenase 2
(ALDH2) to form acetate, which can then enter the bloodstream or can enter the Krebs cycle in
hepatocyte mitochondria to be completely oxidized to form CO 2 and water. ADH and ALDH2 both require
+
nicototinamide adenine dinucleotide (NAD ) to form NADH, which can alter the cellular redox state.
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Ethanol alters the hepatic cellular redox state and energy metabolism
The oxidation of ethanol to acetate contributes to oxidative stress. The enzymes
ADH and ALDH require the cofactor nicotinamide adenine dinucleotide (NAD+) which is
reduced to NADH in order to metabolize ethanol. The consequence of this is shifting
the NADH/NAD+ ratio, which changes the cellular redox state. Generally, the increase
in NADH creates a more reducing environment in the cytosol and the mitochondria [15].
The redox active semiquinone intermediates within the electron transport chain
complexes I and III in the mitochondria are also in a more reduced state due to the
increase in NADH, facilitating the reduction of O2 to O2-. Oxidative stress is also
generated from NADPH oxidase activity which is required by CYP2E1 [15]. Since
oxidative metabolism by CYP2E1 is NADPH depleting, it may negate the protection
against oxidative stress that is conferred by glutathione (GSH) because NADPH is
required in the regeneration of GSH from GSSG by glutathione reductase [17].
Although acetaldehyde is a short lived intermediate in the oxidation of ethanol to
acetate, it is highly toxic and a known carcinogen. In addition to being a source of
oxidative stress, acetaldehyde can readily form adducts with protein, enzymes, and
DNA. The protein adducts formed can inhibit protein secretion, may contribute to
enlargement of the liver, and cause mitochondrial dysfunction leading to cytochrome c
release and activation of apoptotic factors [6, 15, 18]. As the mitochondria become
impaired due to damage incurred from oxidative stress and acetaldehyde adducts, ATP
generation is hindered as is the ability to process acetaldehyde, resulting in an
accumulation of the carcinogen [15].
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The accumulation of NADH has further deleterious effects that serve to alter
energy metabolism. The high concentration of NADH inhibits the oxidation of lactate to
pyruvate in gluconeogenesis and will cause the reverse reaction to predominate
producing lactate [19]. The accumulation of lactate can lead to hypoglycemia and lactic
acidosis [20]. Because fatty acid oxidation creates NADH to be used for ATP
generation, the NADH glut inhibits β-oxidation of fatty acids, activating fatty acid
synthesis instead [19, 21]. These metabolic changes sets events in motion that are
consistent with the first stage of alcoholic liver disease, the development of fatty liver or
hepatic steatosis through the accumulation of triglycerides [21].The second stage is
alcoholic heptatitis, which is associated with cell death and inflammation [19, 22]. The
last stage is cirrhosis as scar tissue develops around the dead cells [19].
The methionine cycle and transsulfuration pathway
The methionine cycle is important to the maintenance of methyl group donors
that are used in transmethylation reactions (Figure 6). In a reaction catalyzed by
methionine adenosyltransferase (MAT), methionine is converted to the methyl group
donor S-adenosylmethionine (SAMe). SAMe serves as the principal methyl donor for a
variety of important biological processes, such as epigenetic regulation of DNA and
proteins, and is involved in the production of phospholipids and polyamines [23]. After
the methyl group leaves, SAMe becomes S-adenosylhomocysteine which is hydrolyzed
to adenosine and homocysteine. Homocysteine is used to synthesize glutathione
(GSH), from cystathionine as part of the transmethylation pathway. Additionally, as an
essential amino acid methionine cannot be synthesized but can be regenerated from
homocysteine through dietary methyl group donors. The folate cycle provides methyl15

tetrahydrofolate (THF) which, through the action of methionine synthetase (MS)
transfers a methyl group to homocysteine to generate methionine, thereby renewing the
methionine cycle [24]. Collectively, we refer to the methionine cycle and the
regeneration of methionine through folate biochemistry as one carbon metabolism.
Ethanol consumption has also been associated with decreases in SAMe/SAH
ratios leading to (or and) an overall decrease in methylation, including DNA methylation
[24]. Hypomethylation of DNA may result from ethanol’s action at several points directly
and indirectly involving one carbon metabolism. Ethanol has been shown to inhibit MS,
restricting the ability to regenerate methionine from homocysteine [25]. There are many
conflicting reports on how ethanol may decrease the activity of MAT, which would
partially explain the decrease in methylation. One study has reported no changes in
MAT level or activity were observed in rats intragastrically fed ethanol for 9 weeks.
Despite this finding, liver biopsies from patients with alcoholic liver disease have shown
decreases in MAT activity, suggesting that MAT may only be affected in later stages of
alcoholic liver disease [24, 26]. Additionally, ethanol can interfere with vitamin B12
absorption [27, 28]. B12 is a required cofactor for the transfer of a methyl group from
THF to homocysteine to form methionine, which is likely to disrupt the methyl donor
pool. Should ethanol inhibit the methionine cycle and transsulfuration pathway, it is
likely that GSH regeneration via transsulfuration derived cysteine would also be
affected, decreasing the hepatocytes ability to scavenge free radicals, decreasing
cellular protection versus oxidant stress.
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Figure 6. Ethanol perturbs the methionine cycle and transsulfuration pathway. The essential amino acid
methionine is regenerated from homocysteine by the folate cycle which provides dietary derived methyltetrahydrofolate (THF). The methyl group is transferred to homocysteine to generate methionine by
methionine synthetase (MS). Catalyzed by methionine adenosyltransferase (MAT) is converted to Sadenosylmethionine (SAMe), the primary methyl donator in the body. S-adenosylhomocysteine (SAH) is
hydrolyzed to form homocysteine as one of the products, beginning the cycle again. Homocysteine is
also used to synthesize glutathione from cystathionine. Ethanol exerts deleterious effects on these cycles
by decreasing MS and MAT activity.
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Lysine Acetylation
Lysine acetylation is a reversible post translational modification that has been
studied and well characterized in the context of histone acetylation for over four
decades [29]. However, the first non-histone protein to be identified as being modified
by lysine acetylation, the tumor suppressor p53, has only come to light within the last
two decades [30]. Since this discovery, the list of lysine acetylated proteins has been
ever expanding. Proteomic studies have collectively identified at least 3,311 proteins
with more than 7,151 lysine acetylation sites [31-33], many of which are enzymes that
catalyze intermediate metabolism in the liver [32]. In general, lysine acetylation of
histone tails is associated with transcription by neutralizing the lysine’s charge and
weakening the interactions between histones and DNA [34]. Understanding the function
of lysine acetylation of non-histone proteins becomes more complex when the diversity
of substrates are considered and may be analogous to phosphorylation in terms of the
various ways in which proteins are regulated [35]. For instance, acetylation of
axonemal tubulin is theorized to contribute to tubulin stability in nerve cells processes
[36, 37]. Some of the key physiological mechanisms that are regulated by non-histone
protein acetylation include cell migration, metabolism and aging as well as in the
pathological context of cancer, neurodegenerative disorders and alcoholic liver disease
[38, 39].
Lysine acetylation is catalyzed by the action of histone acetyltransferases
(HATs). Despite the name, these enzymes modify both histone and non-histone
targets; several have been identified and grouped into 5 subfamilies: HAT1,
Gcn5/PCAF, MYST, p300/CBP, and Rtt109 [40]. HATs from the Gcn5/PCAF, MYST,
18

and p300/CBP families have all been detected in the liver and are identified to have
mostly nuclear substrates. PCAF from the Gcn5/PCAF family is an exception which has
been found to reside in both the nucleus and cytoplasm with substrates including
histones, p53, and cortactin [39]. In prokaryotes and eukaryotes, lysine acetylation
involves the transfer of an acetyl moiety from acetyl-CoA to the ε-amino group from an
N-terminal lysine residue [41]. All HATs that participate in histone and non-histone
acetylation contain a structurally conserved β-sheet helix core region that participates in
acetyl-CoA binding in which the acetyl group serves as the donor for acetylation. The
structurally conserved core region is flanked by variable N- and C- terminal segments
that presumably contribute to substrate specificity [40]. Not much is known about how
HATs are regulated, especially in regards to non-histone protein substrates. There
have been many recent studies that show HAT activity in several families known to
have nuclear substrates is at least enhanced by autoacetylation, but may not be a
requirement for their activity [42-45]. These studies may provide insight into how nonhistone protein acetylation is regulated as well. One such study has shown that a
member of the Gcn5 acetyltransferase family associated with α-tubulin acetylation,
αTAT1, has increased catalytic activity toward microtubules [46]. Other studies
investigating lysine acetylation in Mycobacterium tuberculosis have shown that Gcn5related acetyltransferases are regulated allosterically by cyclic AMP (cAMP) [47, 48].
The removal of an acetyl moiety from lysine residues on proteins is catalyzed by
the better defined deacetylases. There are two major families of deacetylases, 11
belonging to the reduced potassium dependency 3/histone deacetylase 1 family
(Rdp3/Hda1), generally referred to as the histone deacetylases (HDACs), and 7
19

belonging to the Sir2-related protein (sirtuin) family [49]. The two families of
deacetylases are distinguished by their different catalytic mechanisms. HDACs utilize a
highly conserved Zn2+-dependent catalytic core, while Sirt activity requires NAD+ as a
cofactor [49]. Although the catalytic mechanism of the HDAC’s and Sirt’s are fairly well
characterized, not much is known about how they are regulated.
The deacetylases are further grouped into 4 classes. There are three of these
classes in which HDACs are grouped based on size and homology to the yeast
analogues Rdp3/Hda1 for HDACs, and a separate class for Sirts based homology to the
yeast analogue sir2 [49]. HDAC1,2,3 and 8 are members of class I and are found
almost exclusively in the nucleus with primarily histone and transcription factor
substrates [39]. Class II consists of HDAC 4-7,9 and 10 with substrates that are mostly
transcription factors. HDAC6 is the only exclusively cystosolic deacetylase and targets
tubulin and Hsp90. Interestingly, HDAC6 knockout mice have hyperacetylated tubulin
but develop normally with no distinct abnormal phenotype, although these mice had a
slight decrease in bone mineral density [50]. Class III includes the sirtuins, sirt1-7. Sirt1
resides in the nucleus and substrates include histones and transcription factors such as
p53, PGC1-α (peroxisome proliferator-activated receptor-γ coactivator), and the DNA
repair factor Ku70. Each one of these is associated with cell survival, aging and caloric
restriction [51-53]. Sirt2 regulates histones but also deacetylates tubulin and, like
HDAC6, is cytoplasmic [54]. Sirt3-5 are found exclusively in the mitochondria [39].
Sirt6 and 7 reside in the nucleus and target H3K9 (histone 3 lysine 9) and RNA
polymerase I, respectively [55, 56]. Currently, not much is known about the lone
member of class IV, HDAC11.
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Global hepatic lysine hyperacetylation is a recently discovered feature of ethanol
exposure with numerous target proteins having been identified to date in an ever
expanding list [57-59]. These proteins have been discovered to reside in all the major
subcellular compartments including the cytosol, nucleus and mitochondria [39].
Currently, the overall consequences of protein hyperacetylation are still being explored.
. Histone H3 hyperacetylation alters transcription and has been shown to up-regulate
transcription of genes known to be up-regulated with ethanol consumption (ADH and
glutathione S-transferase), while down-regulating genes known to be down-regulated
with ethanol consumption (L-serine dehydratase and CYP 2C11) [39]. Ethanol induced
acetylation of SREBP-1 and PGC-1α leads the enhancement of fatty acid synthesis
[39]. Tubulin is hyperacetylated under ethanol exposure as well. This appears to lead
to microtubule stability, while impairing protein trafficking [39, 60].
The mechanism of ethanol induced hyperacetyation is also under exploration.
Certain experiments on hepatic cells in vitro in the presence of ethanol using inhibitors
of ethanol metabolizing enzymes such as 4-methylpyrazole, an inhibitor of alcohol
dehydrogenase, and cyanamide, which inhibits aldehyde dehydrogenase have
discovered that ethanol metabolism is required for hyperacetylation and that ethanol
may need to be oxidized fully to acetate [60-62]. These studies have involved
microtubules and histone H3, and no reports have explored how other proteins might
respond to inhibition of ethanol metabolism. If similar results were found from such
experiments it would support a role for acetate or acetaldehyde mediating ethanol
induced acetylation. Another hypothesis is that the decrease in NAD+ due to ethanol
metabolism, down-regulates sirtuin activity which requires NAD+ as a cofactor for
21

activity [39]. There has also been evidence for decreased expression of HDAC6, Sirt1,
and Sirt5 with ethanol exposure [58, 63, 64].
Interestingly, many of the proteins identified to be hyperacetylated with ethanol
exposure have been found to reside in the mitochondria [57, 59]. And even though
Sirt3 is thought to be the primary deacetylase in the mitochondria, Sirt3 levels were
unchanged in one study using rats fed an ethanol diet consisting of 36% kcals derived
from ethanol for 6 weeks [59]. However, it has also been shown that Sirt3 can be
inhibited by covalent 4-HNE modifications, which may provide an alternative explanation
for ethanol-derived increases in mitochondrial protein acetylation [63]. To date, there
has been no acetyltransferase identified in the mitochondria which has led to
speculation of a possible non-enzymatic mechanism of acetylation [65]. It has been
shown that Sirt3 activity can deacetylate succinate dehydrogenase flavoprotein, a
subunit of complex II an important component of the electron transport chain, leading to
increased activity in complex II [66]. This finding implies that if Sirt3 activity is impaired
with ethanol consumption, this could potentially lead to decreased activity of complex II
and hinder oxidative phosphorylation.
Research in the area of ethanol induced hyperacetylation is still in its infancy and
much more work needs to be done toward characterizing both the mechanisms and
pathophysiological consequences of this observed phenomenon.
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CHAPTER 2
ROLE OF IRON IN ETHANOL DERIVED HEPATIC STRESS
2.1 Introduction
Throughout human history, alcohol has been the most socially accepted
addictive drug worldwide. It is estimated that alcohol consumption is the third leading
cause of preventable death in the United States alone while globally accounting for up
to 4% of total mortalities [1, 2]. Chronic alcohol use is associated with a number of
diseases including Alzheimer’s disease, liver disease, chronic respiratory disease, heart
disease, diabetes, bone disease, and cancer [18].
Ethanol (CH3CH2OH) is the form of alcohol that is ingested and the primary site
of metabolism occurs in the liver, which is the organ most directly affected by chronic
alcohol use [6]. Ethanol is oxidized in a series of reactions in the liver, first producing
the toxic intermediate acetaldehyde by ADH (alcohol dehydrogenase) in the cytosol,
requiring the reduction of NAD+ to NADH. Then, acetaldehyde is shuttled into the
mitochondria and oxidized by ALDH2 (aldehyde dehydrogenase), also requiring NAD+,
to form acetate [6]. These reactions alter the cellular redox state and energy
metabolism in liver hepatocytes and can lead to alcoholic liver disease. The first stage
of which develops as hepatic steatosis, or “fatty liver” and with continued chronic alcohol
abuse can progress to cirrhosis of the liver [19].
Pathogenesis due to alcohol use arises from a range of sources, all derived from
the consequences of ethanol metabolism. Oxidative stress is thought to be a major
contribution to liver injury. ROS (reactive oxygen species) can be generated from
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acetaldehyde, changes in the cellular redox state, and metabolism of ethanol by
CYP2E1 (cytochrome p450), an alternative cytosolic pathway that engages under high
levels of cellular ethanol, and which is induced following chronic alcohol use [15, 18]. A
key indicator of oxidative stress is the presence of 4-HNE (4-Hydroxynonenal) adducts
that attaches to proteins, formed as a result of lipid peroxidation [67].
Ethanol also has an inhibiting effect on the transmethylation pathway, impacting
the regeneration of methionine in the methionine cycle [24]. When this pathway is
inhibited it reduces the amount of the methyl donor SAMe (S-Adenosyl methionine)
available for reactions requiring methyl groups, such as DNA methylation [24, 26].
Additionally,impacts on the methionine cycle may affect synthesis of the ROS
scavenger glutathione through the transsulfuration pathway, which requires
homocysteine. We speculate that, conversely, ROS derived from ethanol consumption
may lead to glutathione depletion and subsequent reduction in SAMe methyl donor
levels and downstream methyl donor dependent reactions, such as DNA methylation,
as occurs in Syrian hamster liver cells following bromobenzene treatment [68].
Recent studies have shown that chronic alcohol consumption also induces global
lysine hyperacetylation of proteins [39]. Dozens of proteins have been identified as
substrates for hyperacetylation under ethanol exposure that are nuclear, cytosolic and
mitochondrial in origin [57, 59]. The mechanism underlying the increase in acetylation
is currently unknown, although there have been reports of decreases in deacetylase
activity associated with ethanol exposure, such as Sirt1 (silent mating type information
regulation) and HDAC6 (histone deacetylase) [58, 69]. It has also been proposed that
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the NAD+ (nicotinamide adenine dinucleotide) dependent family of deacetylases,
sirtuins, are down regulated because ethanol metabolism depletes free NAD + [39].
Iron is a known mediator of oxidative stress, generating ROS as a product of
Fenton chemistry in which free iron reacts with hydrogen peroxide to form the hydroxyl
radical [5]. Iron is taken in from the diet and absorbed in the small intestines, where it
enters the blood stream, binds to transferrin and is collected in the liver via TfR
(transferrin receptor) activity [7]. Iron in the liver that is not being utilized by biological
processes, such as hemoglobin synthesis, is primarily stored in a non-reactive state
within the ferritin protein, a 24 subunit oligomeric mixture of ferritin heavy chain (FerH)
and light chain (FerL) subunits [5]. Systemic iron availability is regulated by a small
peptide hormone produced by the liver called hepcidin. When up-regulated by
increased iron stores, hepcidin works by triggering the degradation of the iron exporter
protein, ferroportin, effectively inhibiting release of enterocyte-absorbed iron into the
bloodstream [7]. Chronic alcohol use is known to inhibit hepcidin and desensitize the
regulation of its expression to iron levels, leading to increased iron absorption and
hepatic iron overload, one of the hallmarks of alcoholic liver disease [3, 70, 71]. The
risk of liver disease ranging from cirrhosis to hepatocellular carcinoma is greatly
increased in iron overload disorders such as hereditary hemochromatosis, an
autosomal recessive disease in which excess iron is absorbed and deposited in the liver
hepatocytes [72].
In the present study, we were interested in exploring the role of normal dietary
iron levels in the hepatic stress that derives from chronic ethanol consumption. While
many studies have examined this area in the context of iron overload, we were
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interested in determining the impact of reducing dietary iron in ethanol fed mice to give
insight into the role of normal iron levels in ethanol-derived liver damage. We
hypothesized that lowering the amount of dietary iron would reduce oxidative stress in
the liver resulting from chronic ethanol consumption, reducing in turn, the impact of
ethanol on methyl donor availability. Thus, in addition to oxidative stress measurements
we have explored the impact these diets have on methylation while maintaining normal,
adequate levels of methyl donors in the diet. Finally, we evaluated their effect on global
hepatic acetylation and the NAD+/NADH pool to determine if iron availability is involved
in ethanol’s impact in these areas. We found no detectable involvement of oxidant
stress after our chronic ethanol treatment, mild pathological changes to the liver, and
interesting increases in hepatic protein acetylation in ethanol treated mice fed low iron
diets when compared to ethanol treated mice receiving normal dietary iron.

2.2 Materials and Methods
All animal protocols were approved by the Marshall University Institutional Animal
Care and Use Committee. C57BL/6 mice purchased from Jackson Laboratories (Bar
Harbor, Maine) were housed in a AAALAC accredited facility and pair-fed LieberDeCarli liquid diets for 11 weeks and 22 weeks as previously described in the literature
differing only in the amount of iron in the diet [73]. The Lieber-DeCarli diets were
purchased from Dyets, Inc (Bethlehem, PA). The mice were divided into two
experimental groups, normal iron and low iron, with both groups having ethanol and
pair-fed control mice. The ethanol diets consisted of 35% calories from fat, 17% from
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carbohydrate, 18% from protein, and 30% from ethanol with nutritionally adequate
amounts vitamins, minerals, and methyl donors such as folate and choline. Control
mice received an isocaloric amount of carbohydrate in the form of maltose-dextran.
Mice fed a normal iron diet received 55mg/kg of ferric citrate, while the low iron diet
delivered 5mg/kg of ferric citrate.
After a period of 11 weeks to 22 weeks of feeding, the mice were weighed and
then euthanized by exsanguination. Hematocrits were measured and excised livers
were washed in PBS-T, weighed and frozen in liquid nitrogen. The tissue samples were
then stored in a -80ºC freezer. Liver sections were preserved for histology analysis in
buffered formalin.
Liver tissue lysate preparation
Liver tissue was homogenized in whole cell lysis buffer (WCLB) containing 25mM
tris pH 7.4, 1% triton X100, 6% SDS, 1% Na deoxycholate, 150mM NaCl, 200mM
EDTA, and HALT protease inhibitor cocktails from Thermo Scientific (Rockford, IL).
Approximately 15µL of WCLB was used per 1mg of tissue. Liver tissue was taken from
-80°C freezer storage, weighed and ground with 65% of the total amount of WCLB to be
used into fine particles using a pre-chilled mortar and pestle over liquid nitrogen. While
still frozen the particulate matter was transferred into a 10mL polypropylene round
bottom tube. The remaining 35% of WCLB was added to the ground tissue and it was
homogenized on ice with a Tissuemiser polytron blender from Fisher Scientific
(Fairlawn, NJ). The homogenate was centrifuged for 10 minutes, 11,000 RPM, at 4°C
and the supernatant was collected.
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Total protein was quantitated using the BCA protein assay kit obtained from
Thermo Scientific (Rockford, IL). Western blot loading stock with a concentration of
5µg/uL was prepared by diluting lysate in modified 1X Laemmli sample buffer solution at
a final concentration of 2% SDS, 10% glycerol, 63mM tris pH 6.8, 5% βmercaptoethanol, and less than 0.05% bromophenol blue [74]. The samples were then
boiled in water for 10 minutes and slowly cooled to room temperature for at least 30
minutes. Aliquots of stock were made to avoid numerous freeze/thaw cycles, then
stored along with any unused portion of homogenate at -80°C.
SDS-PAGE
Samples were analyzed using SDS-PAGE with the mini-PROTEAN 15-lane gel
system from Bio-Rad (Richmond, CA). The gels were cast using 12% polyacrylamide
resolving gels (0.6M tris pH 8.8, 12% acrylamide/bis 37.5:1, 0.1% SDS, 0.05% APS,
0.1% TEMED) and 5% stacking gels (0.01M tris pH 6.8, 5% acrylamide/bis 37.5:1, 0.1%
SDS, 0.05% APS, 0.1% TEMED). Prior to loading on the gel, the samples were
prepared from western blot loading stock, that was previously frozen at -80°C, to the
desired amount of protein to be loaded and boiled for 2.5 minutes. Gel running buffer
was made from a 10X stock solution (1X = 0.3%(w/v) Tris, 1.44%(w/v) glycine,
0.02%(v/v) SDS). Electrophoresis was performed for approximately 1 hour at 200V,
125mA, and 12W until the dye ran off the gel.
Western Blots
The proteins were transferred using a wet transfer system, the Mini Trans-Blot
Cell from Bio-Rad (Richmond, CA), on to Whatman Protran 0.1µm pore size
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nitrocellulose membranes purchased from GE Healthcare (Little Chalfont, United
Kingdom). The transfer buffer used was made from a 10X stock solution of Tris and
glycine. Transfers were carried out at 4°C for 16 hours using the following power
settings: 30V, 90mA, 25W. Even transfer and equal loading of proteins was evaluated
by Ponceau-S staining the membranes (5%(v/v) acetic acid, 0.1%(w/v) Ponceau-S).
Following transfer and staining, the membranes were blocked for one hour in a
solution containing 5%(w/v) powdered milk and 2%(w/v) bovine serum albumin (BSA) in
1X TBS-T made from a 10X stock solution (1X = 100mM tris, pH 7.4, 0.9%(w/v) NaCl,
0.05%(v/v) tween). The membranes were either washed in TBS-T for 5 minutes and
probed immediately with antibodies, or dried and stored at -4ºC until needed. If the
membranes were dried, they were blocked again before use for 15 minutes, washed
with TBS-T for 5 minutes and then probed. All primary antibodies were incubated with
gentle rocking overnight at 4ºC. Next, the membranes were washed at room
temperature in TBS-T 1 time for 1 minute, 2 times for 5 minutes, and 2 more times for
15 minutes. Secondary horse radish peroxidase (HRP)-conjugated antibodies were
incubated with the membranes at room temperature for one hour with gentle rocking,
then washed with TBS-T for 1 minute, and 4 times at 5 minute intervals. HRP is
activated by Super Signal West Pico chemiluminescent substrate purchased from
Thermo Scientific (Rockford, IL), with 5 minutes incubation time. Lastly, the membranes
were exposed to 8x10 clear blue x-ray film obtained from Thermo Scientific, using a
Kodak Biomax cassette (Rochester, NY). The film was developed in a Mini Medical
series x-ray film developer by American Medical Imaging Solutions (Huntington, WV).
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Densitometry was performed using Un-Scan-It graph digitizing software purchased from
Silk Scientific Inc. (Orem, Utah).
Antibodies
All antibodies were incubated in TBS-T, the 4-HNE antibody being the exception
as it required a dilution in 5% milk, with dilution factors determined empirically.
Additionally, all antibody dilutions were confirmed to have the ability to distinguish a
linear concentration of protein amounts.
The following primary antibodies were used: custom rabbit α-mouse FerL
corresponding to amino acid sequence Ac-EGVGHFFRELAEC (New England Peptide,
Gardner, MA), mouse α-human TfR (Invitrogen, Camarillo, CA), goat α-4-HNE
(Millipore, Billerica, MA), rabbit α-acetyl lysine (Immunechem, Burnaby British Columbia,
Canada); rabbit α-mouse HDAC6, chicken α-mouse Sirt1 and rabbit α-mouse Sirt2 were
obtained from Thermo Scientific (Rockford, IL).
The corresponding secondary antibodies were purchased from: Bio-Rad
(Richmond, CA) goat α-mouse IgG-HRP, goat α-rabbit IgG-HRP, Thermo Scientific
(Rockford, IL), donkey α-goat IgG-HRP Santa Cruz Biotechnology (Dallas, TX), and
rabbit α-chicken IgY-HRP GeneTex (Irvine, CA).
HPLC Analysis of Hepatic SAMe Levels
A 200 mg aliquot of liver was homogenized on ice in 0.4 mM HClO4 and adjusted
to a final 1 ml volume. Mitochondrial and 15,000 x g supernatant suspensions were
added to an equal volume of 0.4 mM HClO4 to precipitate protein. Nuclear samples
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were concentrated by lyophilizing the 1 ml of sample (total liver weight 600-900 mg) and
reconstituting the sample in 125 µl 0.4 mM HClO4. The samples were then centrifuged
at 10,000 x g at 4°C and filtered through 0.45 µM Millex®-HV filters (Millipore; Billericia,
MD). A 20 µl sample of the filtrate was analyzed for whole liver, mitochondrial, and
15,000 x g supernatant fractions, while 40 µl of sample was required for detection of
nuclear SAMe levels. SAMe and SAH levels were detected using a Beckman Coulter
HPLC system (Fullerton, CA) with a 126 Solvent Module and a 166 Variable
Wavelength Detector. The column was a YMC ODS-AQ 3 µm 120 Å 4.6x150 mm
column. The mobile phase was a gradient at a flow of 1 ml/min (Waters Corporation;
Milford, MA). The mobile phase gradient program was 8 minutes of 90:10 A:B followed
by 12 minutes of 60:40 A:B. Mobile phase A consisted of 8 mM 1-heptane sulfonic acid
sodium salt and 50 mM sodium phosphate monobasic (pH 3). Mobile phase B was
100% HPLC grade methanol. The wavelength for detection was 254 nm.
Determination of Hepatic Glutathione.
GSH was determined using a spectrophotometric assay. For the assay, 200 mg
of liver was homogenized in 5% sulfosalicylic acid (SSA) for a final volume of 1 mL.
GSH was assessed using glutathione reductase with 5,5’-dithiobis(2-nitrobenzoic acid)
and NADPH. GSSG was measured by derivitizing the samples with 2-vinylpyridine first
allowing determination of a percentage of oxidized glutathione within the cell.
NAD+/NADH assay
NAD+ and NADH levels were measured using the NAD+/NADH quantification kit
purchased from Biovision (Milpitas, CA). 4-5mg of liver tissue were taken from -80ºC
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storage and homogenized with the polytron blender using the buffer provided by the kit.
Following homogenization of tissue, the samples were clarified by centrifugation at 4ºC
at 11,000RPM for 30 minutes, collecting the supernatant. Aliquots were taken from the
supernatant to determine total protein amounts, and the remaining supernatant was
immediately filtered using Amicon Ultra 10kDa centrifugal filters, purchased from
Millipore (Billerica, MA), to remove any NAD degrading enzymes. The assay was
carried out on the resulting filtrate following the kit instructions.
Statistics
Statistics were generated using one way ANOVA in Microsoft Excel and two
tailed t-tests were conducted where appropriate. P-values were adjusted using the
Bonferroni-Holm correction method to determine significance.
2.3 Results
Our purpose was to determine if alteration of liver iron would alter the ability of
ethanol to impact several endpoints in the liver. We fed mice Liber-DeCarli based liquid
diets (with nutritionally adequate levels of methyl donors) to deliver 55mg/kg of ferric
citrate in the normal iron dietary formulation and 5mg/kg in the low iron diet. Ethanol
concentrations in the diet were steadily increased by 2.5% of Kcals every half week until
they reached 30%. Pair-fed controls received the specific number of calories and equal
nutrients as ethanol fed mice, by replacing the ethanol derived calories with maltosedextran.
Mice were purchased from the Jackson Laboratories at 10 weeks of age, and
allowed to acclimatize to basal normal iron liquid diet for one week prior to starting the
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experiment. The first wave groups (see Table 1) were seeded with 4 mice in each
group. The second and third subsequent waves were also seeded with 4 mice per
group. The groups within each wave started on the respective diets at the same time.
Wave 1 mice were fed experimental diets for 11 weeks, and then weighed, euthanized
and tissues were taken at necropsy. Wave 2 and 3 mice were fed experimental diets
for 22 weeks, and then weighed, euthanized and tissues were taken at necropsy.
Hematocrits were measured on the blood drawn from mice; no differences were
observed (Supplementary Figure 13).

Treatment Group
Ethanol
Pair-Fed Controls

11 Weeks of ethanol
exposure
Normal
Low Iron
Iron
4
4(3)
4
4(3)

22 weeks of ethanol exposure
Normal Iron

Low Iron

8
8(7)

8(7)
8(7)

Table 1. Overall study design. Indicated in the table is the number of mice seeded per group in each
wave. In parenthesis is the number surviving the experiment.

Liver Pathology
In order to evaluate the pathological impact of the ethanol diets histological
sections of liver were prepared and examined; all samples were found to have mild
steatosis, but no progression beyond this stage. Body weights of mice were noted as
well as the liver/body weight ratios as indicated in Figure 7. There were no significant
changes in body weight at 11 or 22 weeks between diet groups. However, on average
there was an approximate 30% increase in liver/body weight ratios in ethanol fed mice
compared to their respective controls at 11 weeks and 22 weeks
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Figure 7. Mouse weight and liver/body weight ratios at time of necropsy. (A) Body weights of 11 and 22
week ethanol fed mice. (B) Liver/body weight ratio of 11 and 22 week ethanol fed mice. Error bars
represent SEM, *significant after Bonferroni-Holm correction.
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Oxidative Stress
Western blots were performed on whole cell liver lysate and probed with an anti4-HNE antibody took look for changes in 4-HNE adduct formation, a key indicator of
lipid peroxidation resulting from ROS. No differences were observed among the diet
groups (Supplementary Figure 14).
Methionine Cycle
In order to evaluate ethanol’s impact on methyl donors, which may impact the
transmethylation pathway as well as the ability to regenerate the ROS scavenger
glutathione, total hepatic SAMe and SAH were determined using HPLC (Figure 8A-B).
Although the data indicate that in 22 week treated mice, lower dietary iron leads to
decreases in SAMe levels and the SAMe:SAH ratio in ethanol treated mice vs pair-fed
controls; the sample size was small, variance was high and the results were not
statistically significant.
Glutathione
Glutathione was assessed with a spectrophotometric assay (Figure 8C-D). No
changes were observed in either total or oxidized glutathione at 22 weeks of ethanol
exposure.
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Figure 8. Hepatic SAMe and glutathione status in 22 week ethanol fed mice. (A) SAMe:SAH ratio in mice
fed ethanol for 22 weeks. (B) Total hepatic SAMe. (C-D) Total hepatic glutathione content and oxidized
glutathione in mice treated with ethanol for 22 weeks, respectively.
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DNA Methylation
Despite no apparent changes in SAMe, we measured global DNA methylation in
order to see if the steady state level of methyl donors was being maintained through
reduction in downstream usage of SAMe. There were no significant differences in DNA
methylation using LUMA between diet groups in mice exposed to ethanol treatment for
22 weeks (Figure 9).

Figure 9. DNA methylation status in mice fed ethanol for 22 weeks. Global DNA methylation was
measured in mice fed ethanol for 22 weeks using a LUMA assay.
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Protein acetylation, NAD+/NADH and iron protein status
Western blot data from liver tissue lysate of wave 1 mice that received ethanol
treatment for 11 weeks is represented in Figure 10A, with densitometry data shown in
10B. The graphs in panel B show relative protein expression normalized to the normal
iron control group. Global hepatic lysine acetylation was shown to be increased in both
ethanol diets with a 62% increase in the normal iron group and a 124% (p<0.05)
increase in the low iron group, over their respective controls. While the low iron control
levels were lower than their normal iron control counterparts, the difference was not
significant at the 0.05 α level. The iron responsive proteins FerL was decreased in both
low iron groups, while TfR expression was elevated by a factor of 3 (p<0.001) in the low
iron ethanol group only. The transcription factor targeting deacetylase Sirt1, was
increased in both ethanol groups 71% and 184% (p<0.05) in the normal iron and low
iron groups, respectively. Interestingly, there was a 2 fold increase (p<0.05) in the low
iron control group. There were no significant changes observed in the tublin
deacetylase, HDAC6.
NAD+ and NADH levels were quantified in the 11 week mice as shown in Figure
12A, there were no significant changes in the ratio of NAD+/NADH or the actual amount
of NAD+ or NADH per 1mg of protein between groups.
Western blotting of whole cell liver tissue lysate was performed on mice receiving
ethanol treatment for 22 weeks in order to analyze protein expression as shown in
Figure 11. Figure 11A depicts a representative western blot image of the proteins of
interest including global hepatic lysine acetylation, the iron responsive proteins FerL and
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TfR, and deacetylases Sirt1 and HDAC6. Densitometry was used to measure relative
protein expression and normalized to the normal iron control groups that were probed
on the same gel. A graphical representation of protein expression for these proteins
from multiple gels is shown in Figure 11B. A 47% (p<0.05) increase in hepatic lysine
acetylation was observed in the normal iron ethanol group and a 142% (p<0.01)
increase in the low iron ethanol group when compared to the normal iron control. There
was an 80% (p<0.001) reduction in hepatic FerL expression in the low iron control group
over the normal iron control, however, FerL expression was found to be decreased by
roughly half in the low iron control group. Conversely, there was a 197% (p<0.05)
increase in TfR expression in the low iron ethanol group and only a 26% increase in the
low iron control group. We did not find significant changes in HDAC6 or Sirt1
expression between diet groups.
Figure 12B represents NAD+ and NADH levels in 22 week mice. There were no
significant changes observed between groups with the NAD+/NADH ratios.
Interestingly, there were changes in NAD+ and NADH amounts per 1mg of protein.
Overall, there was a nearly 2 fold decrease in total NAD+ and NADH together in both
low iron groups over the normal iron control. NAD+ levels were down by 33% (p<0.05)
in the low iron control group and a 42% (p<0.05) decrease in the low iron ethanol group
compared to the normal iron control. There was a similar decrease in NADH in both low
iron groups of 40% (p<0.05) compared to the normal iron control.
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Figure 10. Hepatic lysine acetylation status and protein expression in 11 week ethanol fed mice. (A)
Western blot image of lysine acetylation, iron responsive proteins FerL (ferritin light chain) and TfR
(transferrin receptor), and lysine deacetylases Sirt1 (sirtuin) and HDAC6 (histone deacetylase) from whole
cell liver tissue lysate. (B) Densitometry data demonstrating relative protein expression levels normalized
to the normal iron control group. Error bars represent SEM, *significant after Bonferroni-Holm correction.
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Figure 11. Hepatic lysine acetylation status and protein expression in 22 week ethanol fed mice. (A)
Representative western blot image of lysine acetylation, iron responsive proteins FerL (ferritin light chain)
and TfR (transferrin receptor), and lysine deacetylases Sirt1 (sirtuin) and HDAC6 (histone deacetylase)
from whole cell liver tissue lysate. (B) Densitometry data demonstrating relative protein expression levels
normalized to the normal iron control group. Error bars represent SEM, *significant after Bonferroni-Holm
correction.
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+

+

Figure 12. NAD quantification. (A) NAD /NADH and total NAD+ and NADH levels in 11 week ethanol
+
+
fed mice. (B) NAD /NADH and total NAD and NADH levels in 22 week ethanol fed mice. Error bars
represent SEM, *significant after Bonferroni-Holm correction.
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2.4 Discussion
In the present study, the hypothesis that normal levels of dietary iron play a role
in the impact of ethanol after chronic ethanol consumption was evaluated in mice. After
22 weeks of feeding, despite an increase in liver to body weight ratios of roughly 30%,
we found no direct test result that would indicate significant oxidative stress was
occurring as a result of ethanol treatment, at either normal or low levels of iron intake.
Previous studies have reported significant increases in 4-HNE adducts in rats fed
ethanol, with one study in particular reporting that 4-HNE adducts were amplified by
increased dietary iron in the form of carbonyl iron [67, 70, 75, 76]. However, these
studies have used intragastric catheters to continuously feed the animals high fat diets
containing up to 49% of calories from ethanol for up to 16 weeks, enabling liver
pathology to advance to the stage of cirrhosis and fibrosis. Many studies have utilized
intragastric ethanol feeding to study the chronic effects of alcoholic liver disease in rats
and mice. The advantage is in overcoming the animals’ natural aversion to alcohol.
While intragastric feeding can achieve blood alcohol concentrations (BAC) as high as
500-600mg/dL, Lieber–DeCarli liquid ethanol diets (LDL) can only reach an average of
100-160mg/dL and may be the reason advanced staged liver disease beyond steatosis
is difficult to achieve [77]. Rats that were fed a LDL ethanol diet for a period of 9
months failed to produce pathology in the liver beyond steatosis, however with vitamin A
supplementation combined with ethanol treatment produced necrosis, inflammation and
fibrosis [78]. Indeed, the inclusion of a secondary hepatic stressor such as
lipopolysaccharides, high fat diet, iron, hepatotoxins, or viral proteins appears to be a
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requirement to initiate the progression of cirrhosis or hepatocellular carcinoma in the
LDL feeding model [77]. The employment of LDL ethanol diet alone does, however,
appear to induce CYP2E1, increased triglycerides, changes in iron homeostasis, and
nutritional deficiencies [77].
In order to determine the response to differences in dietary iron content in terms
of iron phenotype, we examined the expression of the iron responsive proteins TfR and
FerL. As expected, the low iron diet group experienced an overall decrease in FerL
expression at both time points when compared to the control groups. TfR levels were
significantly increased in low iron mice when compared to the control groups only at the
22 week time point. We did not see significant changes in the normal iron group.
Of particular interest, TfR was substantially up-regulated in combination with
ethanol treatment and a low iron diet at 11 weeks and 22 weeks relative to the pair fed
controls. Additionally, FerL was up-regulated in the low iron ethanol group compared to
the low iron control at 22 weeks, but not at 11 weeks. Previous studies have reported
that LDL ethanol treatment in rats have led to increased hepatic ferritin expression with
no changes in TfR [79]. This has been shown to correlate with ethanol mediated downregulation of hepcidin, also rendering hepcidin insensitive to its normal response to
increases in hepatic iron stores [3, 79]. In another report, the effect of ethanol on
hepcidin was independent of any direct effects on IRP’s (iron response element binding
proteins), TfR or ferritin [80]. These studies generally took place over the course of a
week of ethanol exposure and did not examine the expression of these iron proteins
over a prolonged period of time. While TfR has been found to be increased in the
hepatic tissue of patients with alcoholic liver disease [71], the use of decreased iron in
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ethanol treatment is unique to this study. We speculate that the low iron diet created an
iron poor systemic environment for the liver cells, leading to the strong reductions in
ferritin that were observed at 11 weeks. Despite this, the levels of intracellular iron were
not low enough by that point to lead to significant increases in transferrin receptor
expression in the non-ethanol fed mice. After 22 weeks of treatment, however, the liver
iron stores were depleted sufficiently to generate a low cellular iron condition consistent
with the observed increase in transferrin receptor expression in the low iron diet group
non ethanol fed mice. The increased TfR expression seen in ethanol treated low iron
fed mice versus their pair fed low iron controls at both time points does not fit current
models, but clearly may play a role in reports that find increased hepatic iron associated
with alcohol consumption [3, 4], as increases in TfR would facilitate increased uptake of
systemic iron. This result is intriguingly consisitent with the finding that, at 22 weeks,
the low iron, ethanol fed mice had a strong rise in ferritin, relative to the low iron, nonethanol pair-fed controls, as the presense of the ferritin may indicate a relative increase
in iron stores between these two groups. This mechanism would also be facilitated if
systemic iron uptake and availability were increased due to the impact of ethanol on
hepcidin secretion, as has been reported [10, 14, 79].
4-Methylpyrazole is an inhibitor of alcohol metabolizing enzymes, and has been
used to abolish the effect of ethanol on hepcidin in cell culture [80]. It might be
interesting to see if 1) TfR is up-regulated in ethanol treated hepatic cells in iron
deficient media; and 2) how these cells might respond if 4-methylpyrazole is introduced
with ethanol treatment.
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Over the last decade it has been discovered that ethanol treatment in mice leads
to global hepatic lysine hyperacetylation in a wide variety of nuclear and non-nuclear
proteins [57, 59]. A novel finding in our study is that a reduction in dietary iron
significantly increases global hepatic lysine hyperacetylation in whole cell lysate from
hepatic tissue of mice exposed to ethanol treatment for 22 weeks compared to ethanol
fed mice receiving a normal iron diet. This finding led to our examination of cellular
NAD+ and NADH levels and the expression of two deacetylases known to be active in
the cytosol.
One prevailing notion is that because alcohol consumption depletes NAD+
though the oxidation of ethanol, perhaps NAD+ dependent sirtuin activity also decreases
with the diminishing supply of NAD+ [39]. We found that the ratio of NAD+/NADH was
not impacted significantly in any of the diet groups at 11 weeks or 22 weeks.
Nevertheless, we were surprised to find that the actual amounts of NAD+ and NADH
were decreased nearly two-fold in the low iron diet group for both ethanol and control
mice at 22 weeks. However, this finding may not be an accurate representation of the
actual cellular redox state. NAD+ and NADH are unevenly distributed throughout
different cellular compartments and can be free or protein-bound [81]. In order to obtain
the ratio of free NAD+/NADH in a specific compartment, one can measure the
concentrations of oxidized and reduced reactants of a suitable near-equilibrium
reaction. Traditionally, lactate/pyruvate concentrations are measured to determine free
cytosolic NAD+/NADH, while acetoacetate/β-hydroxybutyrate concentrations measure
the ratio in mitochondria [82]. Similar methods have been used to detect decreases in
cytoplasmic and mitochondrial NAD+/NADH ratios in rats given intraperitoneal injections
46

of ethanol [83]. However, a decrease in NAD+/NADH ratio has also been observed from
direct quantification of the molecules using a lactate dehydrogenase based cycling
enzyme in mice fed a LDL ethanol diet for 6 weeks consisting of 31% ethanol derived
calories [84]. It might also be worth noting that the LDL diet in this study contained 44%
calories derived from fat, whereas our study used 35%.
Although we did not observe a significant change in the ratio of total
NAD+/NADH, there was a reduced amount of NAD+ in the low iron group, which also
had the highest amount of acetylation in ethanol fed mice. This finding alone might
support the possibility that a decrease in NAD+ leads to decrease sirtuin activity. Sirt1
expression has been found to be down-regulated in mice on a low fat (10%) LDL
ethanol diet for 4 weeks [85]. A second study reported a decrease in both protein and
mRNA of Sirt1 and its target protein PGC-1α in rats fed a diet with 47% ethanol-derived
calories, and 32% fat in the form of long chain triglycerides [64]. Levels were restored
to normal when the fat content was replaced with medium chain triglycerides. The
reverse has been reported where Sirt1 protein expression is increased in mice receiving
LDL ethanol treatment with high saturated fats for a month [86], and in rats
intragastrically fed ethanol diet for the same amount of time [69]. Our study did not find
significant differences in Sirt1 expression at 22 weeks of ethanol feeding. At 11 weeks
Sirt1 was increased in the ethanol fed normal iron and low iron control group, and
further increased in low iron ethanol fed mice. This increase may, in part, be influenced
by the fat content in our diet since previous studies have indicated changes related
directly to the fat content combined with ethanol treatment. It may also be the result of
a yet to be defined feedback mechanism related to alcohol-induced lysine acetylation
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that attenuates over more prolonged ethanol exposure. Notably, at 11 weeks when
Sirt1 expression was increased in ethanol fed mice, a significant increase in lysine
acetylation in low iron ethanol fed mice vs normal iron ethanol fed mice was not
apparent. After 22 weeks, when Sirt1 levels were equivalent between the groups, low
iron ethanol fed mice had significantly more acetylation than normal iron ethanol fed
mice. Acetylation status of PGC-1α, a 113kDa protein that regulates gluconeogenesis
and a substrate of Sirt1, is another commonly used indicator of Sirt1 activity [85].
However, the protein was not apparent on the lysine acetylation western blots.
In order to determine if there were changes in deacetylase activity that are not
dependent on NAD+, we chose to examine HDAC6 expression. HDAC6 is a
microtubule deacetylase and is the only exclusively cytosolic HDAC found in the liver
[39]. Tubulin hyperacetylation is a feature that is known to occur with ethanol treatment
in WIF-B and rats [58, 60]. In ethanol treated hepatic cells, HDAC6 expression has
been shown to decrease slightly [58]. Additionally, HDAC6 binding to microtubules is
impaired, presumably, due to ethanol induced modification of tubulin mediated by
acetaldehyde [58]. To our knowledge, HDAC6 expression has not been examined in
vivo with long term ethanol treatment. In the present study we did not find an
appreciable change in HDAC6 expression at 11 weeks or 22 weeks, supporting the idea
that HDAC6 activity may be impaired rather than its expression, or that this may not
significantly impact overall protein acetylation which results from ethanol treatment.
Despite our attempts to detail the mechanism behind ethanol induced
acetylation, it remains elusive, and to date there has been nothing in the literature to
suggest that iron inhibits lysine acetylation or is a requirement for lysine deacetylation.
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Further studies are needed to determine why the reduction of dietary iron leads to an
increase global lysine acetylation and a reduction in the amount of NAD+ and NADH in
the context of chronic ethanol consumption. It can be deduced that the level of iron by
itself has no significant effect on acetylation status since the presence of ethanol was a
requirement for hyperacetylation. It has recently been discovered that an enzyme
required in the earliest steps of NAD de novo biosynthesis, quinolinate synthetase is an
iron-sulfur cluster containing enzyme [87, 88]. It might interesting to perform an assay
on quinolinate synthetase activity on hepatic tissue or cells starved of iron.
Nevertheless, while it is tempting to blame the phenomenon of hyperacetylation on the
decrease in NAD+, the required cofactor for sirtuin deacetylase activity, we found no
increase in acetylation of the low iron non-ethanol fed mice. If the increase in
acetylation due to low iron stems from a decrease in sirtuin activity, then it seems to be
only detectable against a background of high acetylation. Future studies could also
include an assessment of acetyltransferase activity in the liver with low iron and ethanol.
Determining the amount of acetate in the liver could also provide useful information
since it is required for acetyl group donation and there is evidence in histones that nonenzymatic lysine acetylation can occur and this possibility might exist within the
mitochondria as well since there has been no mitochondrial acetyltransferase
discovered to date [65]. Therefore, a simple explanation could be that low iron
somehow has an impact on acetate processing, perhaps leading to increased acetateprotein interaction which in turn leads to increased acetylation.
In the present study we found that decreasing dietary iron has surprising effects
on iron homeostasis, NAD levels and lysine acetylation when compared to normal
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dietary iron intake. Measurements of oxidative stress and methylation status were
unchanged between ethanol and control groups, with no apparent association to dietary
iron. Conversely, after 22 weeks of treatment, low levels of dietary iron were associated
with decreased total nicotinamide NAD+/NADH levels, and increased ethanol-derived
lysine hyperacetylation. Investigation of the expression of two protein deacetylases,
Sirt1 and HDAC6 did not indicate the expression of these proteins were responsible for
the observed impact of the low iron diet on protein hyperacetylation. Low iron diets
predictably led to decreases in ferritin expression after both 11 and 22 weeks, while TfR
expression was only increased at the 22 week time point. Ethanol consumption led to
increased TfR expression over the low iron pair-fed controls at both time points.
Additionally, ferritin expression was increased in the low iron ethanol 22 week group
relative to the low iron pair fed controls, indicating normal iron homeostatic mechanisms
were disrupted by ethanol in a low iron setting. The results of this study suggest that
the trend for chronic alcohol consumers to increase hepatic stores of iron may involve
alterations in transferrin receptor regulation which would interfere with dietary
management of iron loading using a strategy of reduced iron consumption. More
research in this area is needed to fully interpret the observations relating to ethanol
consumption and iron deficiency.
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2.5 Supplementary Data

Supplementary Figure 13. Hematocrit data from mice fed ethanol for 11 and 22 weeks. Hematocrit data
was taken from the mice at the time of sacrifice. No significant changes were observed among diet
groups.

Supplementary Figure 14. Densitometry data of 4-HNE modifications in mice fed ethanol for 11 and 22
weeks normalized to the normal iron control group. 4-HNE adducts were measured by western blotting
using an anti-4-HNE antibody. No significant changes were observed among diet groups.
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Supplementary Figure 15. Ponceau-S stain of membranes used for western blotting of 11 week ethanol
fed mice.
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Supplementary Figure 16. Ponceau-S stain of membranes used for western blotting of 22 week mice.
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Supplementary Figure 17. Western blots and ponceau-S stains of 22 week mice.
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